



Contents lists available at ScienceDirect

Asian Pacific Journal of Tropical Disease

journal homepage: www.elsevier.com/locate/apjtd

Document heading

doi:

© 2013 by the Asian Pacific Journal of Tropical Disease. All rights reserved.

Antidiabetic effects of *Momordica charantia* (bitter melon) and its medicinal potency

Baby Joseph*, D Jini

Interdisciplinary Research Centre, Department of Biotechnology, Malankara Catholic College, Mariagiri, Kaliakkavilai – 629153, Kanyakumari District, TamilNadu, India

PEER REVIEW

Peer reviewer

Arun Kumar, Associate Professor, Department of Biochemistry, International Medical School (IMS), Management and Science University (MSU) Shah Alam Campus, Selangor, Malaysia.

Tel: +60116280732

E-mail: arun732003@gmail.com**Comments**

This is a general review paper which have not authenticity. Over all it is a good compilation of previously published papers related to *Momordica charantia* as a medicinal plant in controlling the blood sugar. As such a lot is known by common mass, that *Momordica charantia* is beneficial towards controlling diabetes but this review article unveiled so many intricate details of the plant and its applied aspects in medicine.

(Details on Page 99)

ABSTRACT

Diabetes mellitus is among the most common disorder in developed and developing countries, and the disease is increasing rapidly in most parts of the world. It has been estimated that up to one-third of patients with diabetes mellitus use some form of complementary and alternative medicine. One plant that has received the most attention for its anti-diabetic properties is bitter melon, *Momordica charantia* (*M. charantia*), commonly referred to as bitter gourd, karela and balsam pear. Its fruit is also used for the treatment of diabetes and related conditions amongst the indigenous populations of Asia, South America, India and East Africa. Abundant pre-clinical studies have documented in the anti-diabetic and hypoglycaemic effects of *M. charantia* through various postulated mechanisms. However, clinical trial data with human subjects are limited and flawed by poor study design and low statistical power. The present review is an attempt to highlight the antidiabetic activity as well as phytochemical and pharmacological reports on *M. charantia* and calls for better-designed clinical trials to further elucidate its possible therapeutic effects on diabetes.

KEYWORDS

Momordica charantia, Hypoglycaemic agents, Diabetes, Bitter melon, Medicinal plant, Bioactive compounds, Insulin, Glucose metabolism

1. Introduction

Diabetes mellitus is considered as one of the five leading causes of death in the world^[1]. Diabetes mellitus is a major global health concerning with a projected rise in prevalence from 171 million in 2000 to 366 million in 2030^[2]. It is a syndrome of disordered metabolism, usually due to a combination of hereditary and environmental causes, resulting in abnormally high blood sugar levels (hyperglycemia)^[3]. Being a major degenerative disease,

diabetes is found in all parts of the world and it is becoming the third most lethal disease of mankind and increasing rapidly^[4]. It is the most common endocrine disorder, affecting 16 million individuals in the United States and as many as 200 million individuals worldwide. Diabetes has been a clinical model for general medicine^[5]. Complementary and alternative medicine involves the use of herbs and other dietary supplements as alternatives to mainstream western medical treatment. A recent study has estimated that up to 30% of patients with diabetes mellitus

*Corresponding author: Baby Joseph, Interdisciplinary Research centre, Department of Biotechnology, Malankara Catholic College, Mariagiri, Kaliakkavilai P.O. 629153, Kanyakumari District, Tamil Nadu, India.

Tel: 04651-244156, +919790403221

E-mail: petercmisicentist@yahoo.com

Foundation Project: This work was financially supported by CSIR, Head HRDG, New Delhi (Grant No. 27/0237/10 EMR II).

Article history:

Received 15 Dec 2012

Received in revised form 17 Dec, 2nd revised form 22 Dec, 3rd revised form 28 Dec 2012

Accepted 4 Feb 2013

Available online 28 Apr 2013

use complementary and alternative medicine[6].

Medicinal plants and its products continue to be an important therapeutic aid for alleviating the ailments of human kind[7–9]. Herbs for diabetes treatment are not new. Since ancient times, plants and plant extracts were used to combat diabetes. Many traditional medicines in use are derived from medicinal plants, minerals and organic matter. The World Health Organization (WHO) has listed 21 000 plants, which are used for medicinal purposes around the world. Among them, 150 species are used commercially on a fairly large scale[1,10].

Momordica charantia (*M. charantia*), also known as bitter melon, karela, balsam pear, or bitter gourd, is a popular plant used for the treating of diabetes-related conditions amongst the indigenous populations of Asia, South America, India, the Caribbean and East Africa[11,12]. Its fruit has a distinguishing bitter taste, which is more pronounced as it ripens, hence the name bitter melon or bitter gourd. Biochemical and animal model experiments have produced abundant data and hypotheses accounting for the anti-diabetic effects of *M. charantia*. In comparison, clinical studies with human subjects are sparse and low quality in design.

Diabetes mellitus is well known clinical entity with various late complications like retinopathy, neuropathy, nephropathy, *etc.* Natural products are known to play an important role in pharmaceutical biology[13]. Specific plant knowledge may provide insight for strategic consumption and sustainable use. The alternate medicine system is now gaining momentum with the knowledge of active principles identified from plant species[14]. *M. charantia* has significant antidiabetic as well as hypolipidemic activity so that it can be used as an adjuvant along with allopathic treatment of medicine to treat diabetes as well as to delay the late complications of diabetes. In the present review, we have elucidated the possible antidiabetic activity of *M. charantia* and its medicinal potency responsible for the hypoglycemic activity.

2. Plant-based anti-diabetic medicine

Plant-based medicine has been used cost-effectively worldwide to treat diabetes. In fact, in many parts of the world, especially poor countries, this may be the only form of therapy available to treat diabetic patients. There are several reviews by different authors about anti-diabetic herbal plants[1,14–17]. Ayurveda and other traditional medicinal systems for the treatment of diabetes describe a number of plants used as herbal drugs. Hence, they play an important role as alternative medicine due to less side effects and low cost. The active principles present in medicinal plants have been reported to possess pancreatic β cells regenerating, insulin releasing and fighting the problem of insulin resistance[18]. Hyperglycemia is involved in the etiology of development of diabetic complications. Hypoglycemic herbs increase insulin secretion, enhance glucose uptake by adipose or muscle tissues and inhibit glucose absorption from intestine and glucose production from liver[19]. Insulin

and oral hypoglycemic agents like sulphonylureas and biguanides are still the major players in the management, but there is quest for the development of more effective anti-diabetic agents.

From the current literature, it is evident that *M. charantia* is the most widely used and popular anti-diabetic plant. Thus, this review will concentrate mainly on *M. charantia* and its anti diabetic properties.

3. The profile of *M. charantia*

3.1. Plant description

M. Charantia (bitter melon or bitter gourd) (Figure 1) is a flowering vine in the family Cucurbitaceae. It is a tropical plant that is widely cultivated in Asia, India, East Africa, and South America for its intensely bitter fruits that are commonly used in cooking and as a natural remedy for treating diabetes[20]. It is a climbing perennial that usually grows up to 5 m, and bears elongated fruits with a knobbly surface. It is a useful medicinal and vegetable plant for human health and one of the most promising plants for diabetes[21].



Figure 1. *M. charantia* plant.

3.2. Nutrient profile

Bitter melon is a powerful nutrient-dense plant composed of a complex array of beneficial compounds. These include bioactive chemicals, vitamins, minerals and antioxidants

which all contribute to its remarkable versatility in treating a wide range of illnesses. The fruits contain high amounts of vitamin C, vitamin A, vitamin E, vitamins B1, B2 and B3, as well as vitamin B9 (folate). The caloric values for leaf, fruit and seed were 213.26, 241.66 and 176.61 Kcal/100 g respectively[22].

The fruit is also rich in minerals including potassium, calcium, zinc, magnesium, phosphorus and iron, and is a good source of dietary fiber (bitter melon “monograph”, 2008). Medicinal value of bitter melon has been attributed to its high antioxidant properties due in part to phenols, flavonoids, isoflavones, terpenes, anthroquinones, and glucosinolates, all of which confer a bitter taste[23].

3.3. Phytochemistry

The main constituents of bitter melon which are responsible for the antidiabetic effects are triterpene, proteid, steroid, alkaloid, inorganic, lipid, and phenolic compounds[24,25]. Several glycosides have been isolated from the *M. charantia* stem and fruit and are grouped under the genera of cucurbitane-type triterpenoids[26,27]. In particular, four triterpenoids have AMP-activated protein kinase activity which is a plausible hypoglycaemic mechanism of *M. charantia*[27].

M. charantia fruits consist glycosides, saponins, alkaloids, reducing sugars, resins, phenolic constituents, fixed oil and free acids[28]. *M. charantia* consists the following chemical constituents including alkaloids, charantin, charine, cryptoxanthin, cucurbitins, cucurbitacins, cucurbitanes, cycloartenols, diosgenin, elaeostearic acids, erythrodiol, galacturonic acids, gentisic acid, goyaglycosides, goyasaponins, guanylate cyclase inhibitors, gypsogenin, hydroxytryptamines, karoundiols, lanosterol, lauric acid, linoleic acid, linolenic acid, momorcharasides, momorcharins, momordenol, momordicilin, momordicin, momordicinin, momordicosides, momordin, momordolo, multiflorenol, myristic acid, nerolidol, oleanolic acid, oleic acid, oxalic acid, pentadecans, peptides, petroselinic acid, polypeptides, proteins, ribosome-inactivating proteins, rosmarinic acid, rubixanthin, spinasterol, steroidal glycosides, stigmasta-diols, stigmasterol, taraxerol, trehalose, trypsin inhibitors, uracil, vacine, v-insulin, verbascoside, vicine, zeatin, zeatin riboside, zeaxanthin, zeinoxanthin amino acids-aspartic acid, serine, glutamic acid, thscinne, alanine, g-amino butyric acid and pipercolic acid, ascorbigen, b-sitosterol-d-glucoside, citrulline, elasterol, flavochrome, lutein, lycopene, pipercolic acid. The fruit pulp has soluble pectin but no free pectic acid. Research has found that the leaves are nutritious sources of calcium, magnesium, potassium, phosphorus and iron; both the edible fruit and the leaves are great sources of the B vitamins[29].

3.4. Bioactive compounds

Based on the multitude of medical conditions that bitter melon can treat, scientists are more and more interested in studying its bioactive compounds and their actions on

the body. However, as many studies report, there has been substantial emphasis on the anti-diabetic compounds and their hypoglycemic properties[30,31]. A number of reported clinical studies have shown that bitter melon extract from the fruit, seeds, and leaves contain several bioactive compounds that have hypoglycemic activity in both diabetic animals and humans[32,33].

Momordicine II and 3-hydroxycucurbita-5, 24-dien-19-al-7, 23-di-O-β-glucopyranoside (4), were isolated as saponins from *M. charantia*. Both compounds showed significant insulin releasing activity in MIN6 β-cells at concentration of 10 and 25 μg/mL[34]. The major compounds that have been isolated from bitter melon and identified as hypoglycemic agents include charantin, polypeptide-p and vicine.

3.4.1. Charantin

Charantin is a typical cucurbitane-type triterpenoid in *M. charantia* and is a potential substance with antidiabetic properties[35,36]. Pitiphanpong *et al.* demonstrated that charantin could be used to treat diabetes and can potentially replace treatment[37]. It is a mixture of two compounds, namely, sitosteryl glucoside and stigmasteryl glucoside[37]. Chen *et al.* isolated 14 cucurbitane triterpenoids, kuguacins, including two pentanorcucurbitacins, one octanorcucurbitacin, and two trinorcucurbitacins, along with six known analogues from the vines and leaves of *M. charantia*[38]. The charantin from bitter melon fruit was extracted and estimated by high performance thin layer chromatographic method[39].

Studies have reported that the compound is more effective than the oral hypoglycemic agent tolbutamide[12]. In a study, two aglycones of charantin were isolated and identified as sitosterol and stigmastadienol glycosides, however, when tested separately for their hypoglycemic effects *in vivo*, these two constituents did not produce any notable changes in blood glucose levels[40]. This is an indication that charantin may contain other specific components, yet to be identified, that are responsible for the hypoglycemic activity observed in diabetics.

3.4.2. Polypeptide-p

Bitter melon is one of the most commonly used vegetable that contains polypeptide-p and is used to control diabetes naturally[41]. Polypeptide-p or p-insulin is an insulin-like hypoglycemic protein, shown to lower blood glucose levels in gerbils, langurs and humans when injected subcutaneously[42]. The p-insulin works by mimicking the action of human insulin in the body and thus may be used as plant-based insulin replacement in patients with type-1 diabetes[43]. Recently, Wang *et al.* have cloned and expressed the 498 bp gene sequence coding for the *M. charantia* polypeptide p gene and have also proved the hypoglycemic effect of the recombinant polypeptide in alloxan induced diabetic mice[44]. The oral intake of the extract from bitter melon seeds does produce hypoglycemic effects in streptozotocin (STZ) induced type-1 diabetic rats[32]. This indicates that compounds in bitter melon seeds other than p-insulin may also be effective in the treatment

of type-1 diabetes.

3.4.3. Vicine

The other major compound that has been isolated from the seeds of bitter melon is a glycol alkaloid known as vicine^[45]. This pyrimidine nucleoside has been shown to induce hypoglycemia in non-diabetic fasting rats by intraperitoneal administration^[46]. However, vicine found in fava bean has been shown to induce favism, an acute disease characterized by hemolytic anemia, in individuals with a hereditary loss of the enzyme glucose-6-phosphatodehydrogenase^[47]. Although there have been no reports on favism induced by bitter melon, individuals susceptible to the disease should avoid eating the fruit. Further studies are required to ensure the safety and efficacy of using vicine to treat hyperglycemia.

3.4.4. Other components

Many other bitter melon constituents have been identified and isolated by various extraction techniques. The first study to show the *in vivo* hypoglycemic activity of the major compounds of bitter melon was done by a group of Japanese scientists. They isolated 11 compounds by fractionation of a methanol extract from dried bitter melon fruits. The structure of three cucurbitane triterpenoids were determined, as well as two other major compounds that were tested and shown to significantly lower blood glucose levels in diabetic mice^[21]. Four compounds that may be responsible for the bitter taste of the plant were isolated and identified as momordicosides K and L, and momordicines I and II. The last two compounds isolated were identified as sitosterol and stigmastadienol, the aglycones of charantin^[40].

4. Medicinal properties of *M. charantia*

Bitter melon is traditionally known for its medicinal properties such as antidiabetic, anticancer, anti-inflammation, antiviral, and cholesterol lowering effects. It contains many phenolic compounds that may have the potential as antioxidant and antimutagen^[25,48]. The fruit, stems, leaves and roots of bitter melon have all been used in traditional medicine to help treat ailments such as hyperlipidemia, digestive disorders, microbial infections and menstrual problems^[49]. Bitter melon has been shown to possess powerful antiviral properties that can stimulate the immune system and activate the body's natural killer cells to help fight off viruses such as white spot syndrome virus and human immunodeficiency virus^[50–52]. Studies have also shown that bitter melon has anti-carcinogenic properties and can be used as a cytotoxic agent against many types of cancer^[53]. Ray *et al.* showed that the extract of bitter melon modulates signal transduction pathways for inhibition of breast cancer cell growth and can be used as a dietary supplement for prevention of breast cancer^[54].

Bitter melon extract can also be used as a broad-spectrum antibacterial agent to fight off infections caused by *Escherichia coli*, *Salmonella*, *Staphylococcus aureus*, *Staphylococcus*, *Pseudomonas*, and *Streptobaccilus*^[55]. In

addition, the plant possesses anti-helminthic properties, which are effective in the treatment of malaria. Traditionally, bitter melon has also been used as an abortifacient agent used to induce abortions. Therefore, pregnant women are advised to avoid consumption of the plant^[50]. The extract of the seed also have antispermatic effect^[56].

5. Anti-diabetic effect of *M. charantia*

There are many traditional herbal remedies that have been used to treat diabetes in Asia and other developing countries^[16,57–59]. *M. charantia* is one of the plants that has been investigated thoroughly for the treatment of diabetes^[60]. With the traditional use supported by modern scientific evidence of the beneficial function of *M. charantia*, it is one of the most promising plants for diabetes today^[11,61]. Investigation of the traditional uses of *M. charantia* in India revealed that it is one of the most important plant for lowering blood glucose levels in patients with diabetes^[43].

5.1. Possible modes of action of *M. charantia* and its extract

M. charantia and its various extracts and components are believed to exert their hypoglycemic effects via different physiological, pharmacological and biochemical modes^[62–64]. The possible modes of the hypoglycemic actions of *M. charantia* and its various extracts and compounds are its hypoglycemic effect^[67,70], stimulation of peripheral and skeletal muscle glucose utilisation^[71,72], inhibition of intestinal glucose uptake^[73–75], inhibition of adipocyte differentiation^[76], suppression of key gluconeogenic enzymes^[77,78], stimulation of key enzyme of HMP pathway^[77], and preservation of islet β cells and their functions^[66]. Today, over 140 different studies worldwide have investigated anti-hyperglycemic and hypoglycemic effects of the different extracts and ingredients of *M. charantia* in both human and animal models^[32,33,62].

According to Kim and Kim, *M. charantia* extract suppressed the activation of mitogen-activated protein kinases (MAPKs) including stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), p38, and p44/42, and the activity of NF- κ B^[65]. The findings suggest that *M. charantia* protects pancreatic β -cells through down-regulation of MAPKs and NF- κ B in MIN6N8 cells. A similar study suggest that *M. charantia* improves the serum and liver lipid profiles and serum glucose levels by modulating PPAR- γ gene expression^[66]. According to Ragasa *et al.*, clerosterol and 5 α -stigmasta-7-en-3 β -ol were isolated as sterols from *M. charantia* having significant hypoglycemic effects^[67]. *M. charantia* was identified to possess a potent neuroprotective activity against global cerebral ischemia-reperfusion induced neuronal injury and consequent neurological deficits in diabetic mice^[68]. Protein tyrosine phosphatase 1B (PTP1B), a negative regulator of insulin signaling, has served as a potential drug target for the treatment of type 2 diabetes^[69].

M. charantia, its extracts and isolated components are believed to exert their hypoglycaemic effects via different

physiological and biochemical processes. These include insulin secretagogue like effect, stimulation of skeletal muscle and peripheral cell glucose utilization, inhibition of intestinal glucose uptake, inhibition of adipocyte differentiation, suppression of key gluconeogenic enzymes, stimulation of key enzymes, HMP pathway and preservation of pancreatic islet cells and their functions.

5.2. Preservation of pancreatic β cells and insulin secretion

It was previously demonstrated by Jeewathayaparan *et al.* that oral administration of *M. charantia* could lead to the secretion of insulin from endocrine pancreatic β cells[79]. This observation was further confirmed by Ahmed *et al.* who investigated the effect of daily oral administration of *M. charantia* fruit juice and the distribution of α , β and δ cells in the pancreas of STZ-induced diabetic rats using immunohistochemical methods[80]. The feeding of alcoholic extract from *M. charantia* showed definite improvement in the islets of Langerhans[81].

Physiological experiments have also shown that *M. charantia* can stimulate insulin secretion from the endocrine pancreas and elicit glucose uptake in the liver[74]. Current evidence therefore indicates that the recovery and subsequent increase in the number of insulin producing cells followed by the release of insulin may be part of the several pathways by which *M. charantia* exerts its hypoglycemic effects. In addition to the properties mentioned above, *M. charantia* and its extracts may possess cell-like proliferation and growth-like properties similar to that of insulin[82]. Nevertheless, further experiment are required, at least at the molecular level, to determine the precise mechanisms whereby *M. charantia* can either repair damaged β cells or prevent their death.

5.3. *M. charantia* and glucose metabolism

Insulin plays a major biochemical role in stimulating the uptake of glucose by different cells of the body for the production of energy[83,84]. Since *M. charantia* and its various extracts and components have been reported to exert hypoglycemic effects, and then it is important to understand whether *M. charantia* may have a direct effect in inducing a reduction in blood glucose level[62]. Previous studies have shown that both the aqueous and alcoholic extracts of the fruit of *M. charantia* can inhibit the activities of fructose 1, 6-diphosphatase and glucose-6-phosphatase and at the same time stimulating the action of glucose-6-phosphatase dehydrogenase[85]. It was previously reported that *M. charantia* and its various extracts can stimulate peripheral cell glucose uptake[71,72]. A number of studies have investigated the effect of the powder and chloroform extract of *M. charantia* in comparison with insulin on glucose and amino acid uptakes by skeletal L6 myotubes and Na^+ and K^+ glucose uptakes by jejunum brush border membrane vesicles in both age-matched control and STZ-induced diabetic rats. The results show that either the lyophilized fruit juice or chloroform extract at 5–10 $\mu\text{g}/\text{mL}$ can stimulate ^3H -deoxyglucose and ^{14}C -Me AIB (N-methyl-

amino- α -isobutyric acid) uptakes by L6 myotubes. These effects were similar in magnitude to the effects obtained with 100 nmol/L insulin. Incubation of either insulin or *M. charantia* juice in the presence of wortmannin (a phosphatidylinositol 3-kinase inhibitor) resulted in a marked inhibition of ^3H -deoxyglucose uptake by L-6 myotubes[71]. Together, the results have clearly demonstrated that *M. charantia* contains insulin like properties, similar to one phytochemical component of *M. charantia* called V-insulin[62].

In addition to its insulin-like effects on skeletal muscle cells, daily oral intake of *M. charantia* fruit juice over a period of 10 weeks significantly reduced the amount of Na^+ and K^+ -dependent ^{14}C -D-glucose absorbed by rat jejunum brush border membrane vesicle compared to vesicles obtained from STZ-induced diabetic rats[80]. Taken together, these results clearly demonstrated that *M. charantia* and its extracts can directly regulate blood glucose via two mechanisms. Firstly, it can regulate how much glucose is absorbed by the gut into the blood following a meal and secondly, it can stimulate glucose uptake into skeletal muscle cells just like insulin. Moreover, it seems to exert its effect via the same intracellular signaling pathways as insulin in regulating glucose metabolism in the body[86].

5.4. Animal studies of *M. charantia*

Various animal studies have repeatedly shown hypoglycaemic effects of the seeds, fruit pulp, leaves and whole plant of *M. charantia* in normal animals[74,87,88]. In particular, *M. charantia* improves glucose tolerance and suppresses postprandial hyperglycaemia in rats[71,75,73], and *M. charantia* extract can enhance insulin sensitivity and lipolysis[89,90]. Some studies also claimed that the hypoglycaemic effect of *M. charantia* was comparable with oral medications such as tolbutamide[70,91], chlorpropamide and glibenclamide[92,93]. Abundant biochemical data have shed light upon possible mechanisms of the anti-diabetic actions of *M. charantia* with the recurring theme being activation of the AMP-activated protein kinase system[94–97]. Other studies suggested a role of the α - and γ -peroxisome proliferator-activated receptors (PPAR α and PPAR γ) which are pivotal in lipid and glucose haemostasis and may mitigate insulin resistance[98,99].

The alcoholic extract of *M. charantia* was quite effective in lowering blood sugar levels and islet histopathology also showed improvement. The lowered blood sugar and improvement in islet histology remained as such even after discontinuation of extract feeding for 15 days[81]. The acetone extract of whole fruit powder of *M. charantia* in doses 0.25, 0.50 and 0.75 mg/kg body weight lowered the blood glucose from 13.3% to 50.0% after 8 to 30-day treatment in alloxan diabetic albino rats, confirming anti hyperglycemic effect of this plant in diabetic animals and humans[100].

5.5. Clinical studies of *M. charantia*

More than 1 000 herbal products have been used by diverse cultures of the world to treat hyperglycemia and

among them bitter melon (*M. charantia*) is one of the most popular herbal resource^[101]. An earlier study on the development of diabetic cataracts demonstrated that blood sugar level–dependent cataract formation was slowed down by the consumption of bitter gourd fruit extract in association with better glucose homeostasis^[102]. Today, processed bitter gourd in the form of capsules or tablets is commonly advertised and sold. The products are marketed under the brand names Gourdin, Karela, and Glucobetic in Canada, India, the United Kingdom, the United States, and many Asian countries. Products can also be ordered online. However, Diabetes UK has released a warning with regard to the use of Karela capsules, because it is not yet known what

dose is safe when taken with other antidiabetic agents, and there is a lack of information on other potential bioactive components of the capsules^[103].

Compared with animal studies, clinical studies regarding the hypoglycaemic effects of *M. charantia* have been sparse and sporadic. Lakholia, a physician, was probably the first to document the therapeutic effect of bitter melon in 1956 using himself as the subject^[104]. As we reviewed in the recent studies fulfilling our search criteria, we noticed that the majority of them lacked proper controls or suffered from poor methodologies without baseline characterizations as tabulated in Table 1.

Table 1

Clinical studies of *M. charantia*.

Study design	Subjects	Form of <i>M. charantia</i> administered	Treatment duration	Outcome measures	Statistical significance	Reference
Open–label uncontrolled supplementation trial	42 individuals	4.8 g lyophilized wild type bitter gourd powder in capsules	3 months	MetS risk factors	Yes	[105]
Random design	26 subjects	Tablets	4 weeks	fructosamine assays	Yes	[60]
Multicenter, randomized, double–blind, active–control trial	4 groups	Capsule contained 500 mg of dried powder of the fruit pulp, containing 0.04–0.05% (w/w) of charantin	4 weeks	Fructose amine	Yes	[32]
Double–blind randomized controlled trial	40 with T2D (twenty trial and twenty control subjects)	Commercial herbal supplement capsules	3 months	HbA1c	No	[106]
Controlled trial	15 with T2D in 3 groups	Methanol extract of ground whole fruit	1 week	Fasting + postprandial blood glucose	Yes	[107]
Randomized controlled trial	50 with T2D (26 trial and 24 control subjects)	Tablets from dried whole fruit	4 weeks	(1) Fasting postprandial blood Glucose (2) Fructose amine	No	[108]
Case series	100 with T2D	Fresh fruit	Single treatment	(1) Fasting glucose (2) 2 h post OGTT	Yes	[109]
Case series	12 with impaired OGTT	Arm 1: dried fruit Arm 2: aqueous extract	3–7 weeks	Arm1: postprandial blood glucose Arm2: postprandial blood sugar þ HbA1c	Arm 1: No Arm 2: Yes	[110]
Case series	14 with T2D and 6 with T1D	Seeds	Single treatment	Postprandial blood glucose	Yes	[111]
Case series	18 with DM	Juice from seedless fruits	Single treatment	OGTT	Yes	[112]
Case series	8 with DM	Powdered dried fruit	1 week	(1) Fasting glucose level (2) Glycosuria (3) OGTT	Yes	[113]
Case series	9 T2D	Fresh fruit juice + fried fruit	Single treatment, then 7–11 weeks	(1) OGTT (2) HbA1c	(1) Yes (with juice) No (with fried fruit) (2) Yes (with fried fruit)	[114]
Case series	19 with DM	‘Polypeptide–p’ isolated from <i>M. charantia</i>	Single treatment	Blood glucose	Yes	[115]
Controlled trial	Trial subjects: 9 DM Control subjects: 5 DM + 5 normal	Aqueous extract refined to subcutaneous injection (v–insulin)	Single treatment	Blood glucose	Yes	[116]
Case series	15 with DM	Fresh fruit juice and dried powder	6–14 weeks	OGTT	No	[117]

6. Conclusion

The concept of food as medicine is a central theme in dietetic and nutritional sciences. *M. charantia* has been used as dietary supplements and ethnomedicine throughout centuries for relieving symptoms and conditions related to what we know in modern days as diabetes. To date, *M. charantia* has been extensively studied worldwide for its medicinal properties to treat a number of diseases^[61]. It is described as a versatile plant worthy of treating almost any disease inflicted on mankind. This may be due to the fact that the plant possesses over 225 different medicinal constituents^[62]. These different compounds may act either separately or together to exert their medicinal effects. In relation to diabetes, only charantin, insulin-like peptide and alkaloid-like extracts possess hypoglycemic properties similar to the plant itself or its crude extracts. These different compounds seem to exert their beneficial effects via several mechanisms to control and treat diabetes mellitus.

Despite the abundant data from biochemical and animal studies, available clinical data as reviewed in the present article are often flawed by small sample size, lack of control and poor study designs. The present review supports the need for better-designed clinical trials with sufficient sample size and statistical power to further indicate the acclaimed efficacy of *M. charantia* as a natural nutritional treatment for diabetes mellitus. In particular, *M. charantia* may be a feasible option for ethnic minorities who have a high prevalence of diabetes but prefer treatment based on natural products according to their cultural beliefs.

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgements

The authors gratefully acknowledged to our Malankara Catholic College Correspondent Fr. Prem Kumar (M.S.W) given encouragement and support for preparation of this manuscript. We wish to express our sincere thanks to Mr. K. Suresh (Dept. of Microbiology), Dr. Sujatha (ICBM) and the research scholars in the Interdisciplinary Research Centre for updated article collection and all the efficient supports of this review preparation. This work was financially supported by CSIR, Head HRDG, New Delhi (Grant No. 27/0237/10 EMR II).

Comments

Background

Diabetes mellitus is one of the leading cause of death in the world. It is one of the major risk factor of cardiovascular disease. This review paper discussed the anti-diabetic effects of *M. charantia* and their medicinal aspects. Overall, the author covered most of the details pertaining to effect of

blood glucose by the plant and highlights its usefulness in controlling blood glucose.

Research frontiers

This paper is a review based on various updates and published works related to hypoglycemic effects of *Momordica charantia*. The materials and methods doesn't confine to this review paper.

Applications

It is not a original research paper but a review so it can be just said that *M. charantia* plays a very promising role in controlling blood glucose and there by controlling the risk factor towards CVD.

Peer review

This is a general review paper which has not authenticity. Over all it is a good compilation of previously published papers related to *M. charantia* as a medicinal plant in controlling the blood sugar. As such a lot is known by common mass, that *M. charantia* is beneficial towards controlling diabetes but this review article unveiled so many intricate details of the plant and its applied aspects in medicine.

References

- [1] Joseph B, Jini D. Insight into the hypoglycaemic effect of traditional Indian herbs used in the treatment of diabetes. *Res J Med Plant* 2011a; **5**(4): 352–376.
- [2] Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract* 2010; **87**: 4–14.
- [3] Patel DK, Prasad SK, Kumar R, Hemelatha S. An overview on antidiabetic medicinal plants having insulin mimetic property. *Asian Pac J Trop Biomed* 2012; **2**: 320–330.
- [4] Ogbonnia SO, Odimegu JI, Enwuru VN. Evaluation of hypoglycemic and hypolipidemic effects of ethanolic extracts of *Treulia africana* Decne and *Bryopyllum pinnatum* Lam. and their mixture on streptozotocin (STZ)- induced diabetic rats. *Afr J Biotech* 2008; **7**(15): 2535–2539.
- [5] Sharma AK, Aggarwal A, Singhal VK. Treatment of diabetes mellitus with indian herbal Drugs. *IJARPB* 2012; **1**(2): 145–153.
- [6] Raman BV, Krishna NV, Rao NB, Saradhi PM, Rao BMV. Plants with antidiabetic activities and their medicinal values. *Int Res J Pharm* 2012; **3**(3): 11–15.
- [7] Joseph B, Raj SJ. Phytopharmacological properties of *Ficus racemosa* Linn – An overview. *Int J Pharm Sci Rev Res* 2010b; **3**(2): 134–138.
- [8] Joseph B, Jini D, Ajisha SU. Phytochemical characterization of herbal drug formulation for arthritis. *Res J Phytochem* 2012; **6**(2): 54–60.
- [9] Singh U, Singh S, Kochhar A. Therapeutic potential of antidiabetic nutraceuticals. *Phytopharmacol* 2012; **2**(1): 144–169.
- [10] Zohary D, Hopf M. *Domestication of plants in the old world*. Oxford: Oxford University Press; 2000, p. 122.
- [11] Cefalu WT, Ye J, Wang ZQ. Efficacy of dietary supplementation with botanicals on carbohydrate metabolism in humans. *Endocr*

- Metab Immune Disord Drug Targets* 2008; **8**: 78–81.
- [12] Cousens G. *There is a cure for diabetes: the tree of life 21 day program*. California: North Atlantic Books; 2008, p. 191–192.
- [13] Joseph B, Raj SJ. Pharmacognostic and phytochemical properties of *Aleo vera* Linn – An overview. *Int J Pharm Sci Rev Res* 2010a; **4**(2): 106–110.
- [14] Joseph B, Jini D. A medicinal potency of *Capparis decidua* – A harsh terrain plant. *Res J Phytochem* 2011b; **5**(1): 1–13.
- [15] Ayodhya S, Kusum S, Anjali S. Hypoglycaemic activity of different extracts of various herbal plants. *IJRAP* 2010; **1**(1): 212–224.
- [16] Malviya N, Jain S, Malviya S. Anti-diabetic potential of medicinal plants. *Acta Pol Pharm* 2010; **67**(2): 113–118.
- [17] Patel P, Harde P, Pillai J, Darji N, Patel B. Antidiabetic herbal drugs a review. *Pharmacophore* 2012; **3**(1): 18–29.
- [18] Kavishankar GB, Lakshmidevi N, Murthy SM, Prakash HS, Niranjana SR. Diabetes and medicinal plants—A review. *Int J Pharm Biomed Sci* 2011; **2**(3): 65–80.
- [19] Hui H, Tang G, Liang VW, Go VLW. Hypoglycemic herbs and their action mechanisms. *Chin Med* 2009; **4**: 11–14.
- [20] Abascal K, Yarnell E. Using bitter melon to treat diabetes. *J Altern Complement Med* 2005; **1**: 179–184.
- [21] Lee SY, Eom SH, Kim YK, Park NI, Park SU. Cucurbitane-type triterpenoids in *Momordica charantia* Linn. *J Med Plants Res* 2009; **3**(13): 1264–1269.
- [22] Bakare RI, Magbagbeola OA, Akinwande AI, Okunowo OW. Nutritional and chemical evaluation of *Momordica charantia*. *J Med Plant Res* 2010; **4**(21): 2189–2193.
- [23] Snee LS, Nerurkar VR, Dooley DA, Efirid JT, Shovic AC, Nerurkar PV. Strategies to improve palatability and increase consumption intentions for *Momordica charantia* (bitter melon): A vegetable commonly used for diabetes management. *Nutr J* 2011; **10**: 78.
- [24] Saeed MK, Shahzadi I, Ahmad I, Ahmad R, Shahzad K, Ashraf M, et al. Nutritional analysis and antioxidant activity of bitter melon (*Momordica charantia*) from Pakistan. *Pharmacologyonline* 2010; **1**: 252–260.
- [25] Budrat P, Shotipruk A. Extraction of phenolic compounds from fruits of bitter melon (*Momordica charantia*) with subcritical water extraction and antioxidant activities of these extracts. *Chiang Mai J Sci* 2008; **35**(1): 123–130.
- [26] Chang CI, Chen CR, Liao YW, Cheng HL, Chen YC, Chou CH. Cucurbitane-type triterpenoids from *Momordica charantia*. *J Nat Prod* 2006; **71**: 1327–1330.
- [27] Tan MJ, Ye JM, Turner N, Hohnen-Behrens C, Ke CQ, Tang CP, et al. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. *Chem Biol* 2008; **15**: 263–273.
- [28] Liu J, Chen J, Wang C, Qui M. New cucurbitane triterpenoids and steroidal glycoside from *Momordica charantia*. *Molecules* 2009; **14**: 4804–4813.
- [29] Kumar DS, Sharathnath VK, Yogeswaran P, Harani A, Sudhakar K, Sudha P, et al. A medicinal potency of *Momordica charantia*. *Int J Pharm Sci Rev Res* 2010; **1**(2): 95–99.
- [30] Islam S, Jalaluddin M, Hettiarachchy NS. Bio-active compounds of bitter melon genotypes (*Momordica Charantia* L.) in relation to their physiological functions. *Funct Foods Health Dis* 2011; **1**(2): 61–74.
- [31] Hazarika R, Parida P, Neog B, Yadav RNS. Binding energy calculation of GSK-3 protein of human against some anti-diabetic compounds of *Momordica charantia* linn (Bitter melon). *Bioinformation* 2012; **8**(6): 251–254.
- [32] Wehash FE, Abpo-Ghanema II, Saleh RM. Some physiological effects of *Momordica charantia* and *Trigonella foenum-graecum* extracts in diabetic rats as compared with cidophage®. *World Academy of Science, Engineering and Technology* 2012; **64**: 1206–1214.
- [33] Fuangchana A, Sonthisombata P, Seubnukarnb T, Chanouanc R, Chotchaisuwatd P, Sirigulsatiene V, et al. Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients. *J Ethnopharmacol* 2011; **134**: 422–428.
- [34] Keller AC, Ma J, Kavalier A, He K, Brillantes AM, Kennelly EJ. Saponins from the traditional medicinal plant *Momordica charantia* stimulate insulin secretion *in vitro*. *Phytomedicine* 2011; **19**: 32–37.
- [35] Krawinkel MB, Keding GB. Bitter melon (*Momordica charantia*): a dietary approach to hyperglycemia. *Nutr Rev* 2006; **64**: 331–337.
- [36] Patel S, Patel T, Parmar K, Bhatt Y, Patel Y, Patel NMD. Isolation, characterization and antimicrobial activity of charantin from *Momordica charantia* linn. Fruit. *Int J Drug Deve Res* 2010; **2**(3): 629–634.
- [37] Pitiphanpong J, Chitprasert S, Goto M, Jiratchariyakul W, Sasaki M, Shotipruk A. New approach for extraction of charantin from *Momordica charantia* with pressurized liquid extraction. *Sep Purif Technol* 2007; **52**: 416–422.
- [38] Chen JC, Liu WQ, Lu L, Qiu MH, Zheng YT, Yang LM, et al. Kuguacins F–S, cucurbitane triterpenoids from *Momordica charantia*. *Phytochem* 2009; **70**: 133–140.
- [39] Thomas CT, Reddy PY, Devanna N. Impact of cooking on charantin estimated from bitter melon fruits using high performance thin layer chromatography. *Int Res J Pharm* 2012; **3**(6): 149–154.
- [40] Harinantenaina L, Tanaka M, Takaoaka S, Oda M, Mogami O, Uchida M, et al. *Momordica charantia* constituents and antidiabetic screening of the isolated major compounds. *Chem Pharm Bull* 2006; **54**: 1017–1021.
- [41] Hellowlife. Polypeptide-P (plant insulin)– A natural treatment for diabetes. The smart living network. [Online] Available from: <http://www.smartlivingnetwork.com/diabetes/b/polypeptide-p-plant-insulin-a-natural-treatment-for-diabetes> [Accessed on 2nd August 2008].
- [42] Tayyab F, Lal SS, Mishra M, Kumar U. A review: Medicinal plants and its impact on diabetes. *World J Pharm Res* 2012; **1**(4): 1019–1046.
- [43] Paul A, Raychaudhuri SS. Medicinal uses and molecular identification of two *Momordica charantia* varieties – a review. *E J Bio* 2010; **6**(2): 43–51.
- [44] Wang Bl, Zhang W, Zhao J, Wang F, Fan L, Hu Z. Gene cloning and expression of a novel hypoglycaemic peptide from *Momordica Charantia*. *J Sci Food Agric* 2011; **91**: 2443–2448.
- [45] Haixia Z, Xiaozuo Z, Yawei W, Mancanq L, Zhide H. Analysis of vicine in bitter melon samples by polyglycol–C8 solid phase with high performance liquid chromatography. *Chin J Anal Chem* 2004; **3**: 408–108.
- [46] Ham C, Wang J. Optimization of conditions for charantin extraction in PEG/Salt aqueous two-phase systems using response surface methodology. *Open Compl Med J* 2009; **1**: 46–50.
- [47] Basch WE, Gabardi S, Ulbricht C. Bitter melon (*Momordica charantia*): A review of efficacy and safety. *Am J Health Syst Pharm* 2003; **60**: 356–359.

- [48] John JK, Simon PW, Staub JE. Bitter gourd: Botany, horticulture, breeding. *Horticulture Rev* 2010; **37**: 101–141.
- [49] Yibchok–Anun S, Adisakwattana S, Yao CY, Sangvanich P, Roengsumran S, Hsu WH. Slow acting protein extract from fruit pulp of *Momordica charantia* with insulin secretagogue and insulinomimetic activities. *Biol Pharm Bull* 2006; **29**: 1126–1131.
- [50] Grover JK, Yadav SP. Pharmacological actions and potential uses of *Momordica charantia*: a review. *J Ethnopharmacol* 2004; **93**: 123–132.
- [51] Balasubramanian G, Sarathi M, Kumar SR, Hameed ASS. Screening the antiviral activity of Indian medicinal plants against white spot syndrome virus in shrimp. *Aquaculture* 2007; **263**: 15–19.
- [52] Bot YS. Screening for the anti HIV properties of the fruit pulp extract of *M. balsamina* [MMLS Dissertation]. Ekpoma: Ambrose Alli University; 2004.
- [53] Haque EM, Alam BM, Hossain SM. The efficacy of cucurbitane type triterpenoids, glycosides and phenolic compounds isolated from *Momordica charantia*: a review. *IJPSR* 2011; **2**(5): 1135–1146.
- [54] Ray RB, Raychoudhuri A, Steele R, Nerurkar P. Bitter melon (*Momordica charantia*) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. *Cancer Res* 2010; **70**(5):1925–1931.
- [55] Saeed S, Tariq P. Antibacterial activities of *Mentha piperita*, *Pisum sativum* and *Momordica charantia*. *Pakistan J Botany* 2005; **37**: 997–1001.
- [56] Patil SA, Patil SB. Toxicological studies of *Momordica charantia* Linn seed extracts in male mice. *Int J Morphol* 2011; **29**(4): 1212–1218
- [57] Jarald E, Joshi SB, Jain DCH. Diabetes and herbal medicines. *Iran J pharm Therap* 2008; **7**(1): 97–106.
- [58] Chauhan A, Sharma PK, Srivastava P, Kumar N, Dudhe R. Plants having potential anti–diabetic activity: A review. *Der Pharmacia Lettre* 2010; **2**(3): 369–387.
- [59] Singh LW. Traditional medicinal plants of Manipur as anti–diabetics. *J Med Plants Res* 2011; **5**(5): 677–687.
- [60] Hasan I, Khatoun S. Effect of *Momordica charantia* (bitter gourd) tablets in diabetes mellitus: Type 1 and Type 2. *Prime Res Med (PROM)* 2012; **2**(2): 72–74.
- [61] Leung L, Birtwhistle R, Kotecha J, Hannah S, Cuthbertson S. Anti–diabetic and hypoglycaemic effects of *Momordica charantia* (bitter melon): a mini review. *Br J Nutr* 2009; **102**: 1703–1708.
- [62] Taylor L. Herbal secrets of the rainforest. In: Texas A, editor. *Bitter melon (Momordica charantia)*. 2nd ed. USA: Sage Press; 2002, p. 1–100.
- [63] Garau C, Cummings E, Phoenix D A, Singh J. Beneficial effects and mechanism of action of *Momordica charantia* in the treatment of diabetes mellitus: a mini review. *Int J Diabetes Metab* 2003; **11**: 46–55.
- [64] Bhushan MS, Rao CHV, Ojha SK, Vijayakumar M, Verma A. An analytical review of plants for anti diabetic activity with their phytoconstituent and mechanism of action. *IJPSR* 2010; **1**(1): 29–46.
- [65] Kim K, Kim HY. Bitter melon (*Momordica charantia*) extract suppresses cytokine induced activation of MAPK and NF–κB in pancreatic β–cells. *Food Sci Biotechnol* 2011; **20**(2): 531–535.
- [66] Cadang V, Gilbert W, Hettiararchy N, Horax R, Katwa L, Devareddy L. Dietary bitter melon seed increases peroxisome proliferator–activated receptor–γ gene expression in adipose tissue, down–regulates the nuclear factor–κB expression, and alleviates the symptoms associated with metabolic syndrome. *J Med Food* 2011; **14**: 86–93.
- [67] Ragasa CY, Alimboyoguen AB, Shen CC, Del Fierro RS, Raga DD. Hypoglycemic effects of tea extracts and sterols from *Momordica charantia*. *J Nat Remedies* 2011; **11**: 44–53.
- [68] Malik ZA, Singh M, Sharma PL. Neuroprotective effect of *Momordica charantia* in global cerebral ischemia and reperfusion induced neuronal damage in diabetic mice. *J Ethnopharmacol* 2011; **133**: 729–734.
- [69] Hoang DM, Trung TN, Hien PTT, Ha DT, Van Luong H, Lee M, et al. Screening of protein tyrosine phosphatase 1B inhibitory activity from some Vietnamese medicinal plants. *Nat Prod Sci* 2010; **16**: 239–244.
- [70] Sărăndan H, Botău D, Ianculov I, Radu F, Rada O, Morar D, et al. The hypoglycemic effect of *Momordica charantia* Linn in normal and alloxan induced diabetic rabbits. *Scientific Papers: Animal Science and Biotechnologies* 2010; **43**(1): 516–518.
- [71] Cummings E, Hundal HS, Wackerhage H, Hope M, Belle M, Adeghate E, et al. *Momordica charantia* fruit juice stimulates glucose and amino acid uptakes in L6 myotubes. *Mol Cell Biochem* 2004; **261**: 99–104.
- [72] Akhtar N, Khan BA, Majid A, Khan S, Mahmood T, Gulfishan, et al. Pharmaceutical and biopharmaceutical evaluation of extracts from different plant parts of indigenous origin for their hypoglycemic responses in rabbits. *Acta Pol Pharm* 2011; **68**(6): 919–925.
- [73] Uebanso T, Arai H, Taketani Y, Fukaya M, Yamamoto H, Mizuno A, et al. Extracts of *Momordica charantia* suppress postprandial hyperglycemia in rats. *J Nutr Sci Vitaminol (Tokyo)* 2007; **53**(6): 482–486.
- [74] Jeong J, Lee S, Hue J, Lee K, Nam SY, Yun YW, et al. Effect of bittermelon (*Momordica Charantia*) on antidiabetic activity in C57BL/6J db/db mice. *Korean J Vet Res* 2008; **48**(3): 327–336.
- [75] Abdollah M, Zuki ABZ, Goh YM, Rezaeizadeh A, Noordin MM. The effects of *Momordica charantia* on the liver in streptozotocin–induced diabetes in neonatal rats. *Afr J Biotechnol* 2010; **9**(31): 5004–5012.
- [76] Nerurkar PV, Lee YK, Nerurkar VR. *Momordica charantia* (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes. *BMC Complement Altern Med* 2010; **10**: 34.
- [77] Shibib BA, Khan LA, Rahman R. Hypoglycaemic activity enzymes glucose–6–phosphatase and fructose–1,6–bisphosphatase and elevation of both liver and red–cell shunt enzyme glucose–6–phosphate dehydrogenase. *Biochem J* 1993; **292**: 267–270.
- [78] Singh J, Cumming E, Manoharan G, Kalasz H, Adeghate E. Medicinal chemistry of the anti–diabetic effects of *Momordica Charantia*: active constituents and modes of actions. *Open Med Chem J* 2011; **5**: 70–77.
- [79] Jeevathayaparan S, Tennekoon KH, Karunanayake EH. A comparative study of the oral hypoglycaemic effect of *Momordica charantia* fruit juice and tolbutamine in streptozotocin induced graded severity diabetes in rat. *Int J Diabetes* 1995; **3**: 99–108.
- [80] Ahmed I, Cummings E, Sharma AK, Adeghate E, Singh J. Beneficial effects and mechanism of action of *Momordica charantia* fruit juice in the treatment of streptozotocin–induced diabetes mellitus in rats. *Mol Cell Biochem* 2004; **261**: 63–70.
- [81] Singh N, Gupta M, Sirohi P, Varsha. Effects of alcoholic extract of *Momordica charantia* (Linn.) whole fruit powder on the pancreatic islets of alloxan diabetic albino rats. *J Environ Biol* 2008; **29**(1): 101–106.
- [82] Parmar K, Patel S, Patel J, Patel B, Patel MB. Effects of bittergourd

- (*Momordica charantia*) fruit juice on glucose tolerance and lipid profile in type-II diabetic rats. *Int J Drug Dev Res* 2011; **3**(2): 139–146.
- [83] Sattiel AL, Khan CR. In insulin signalling and regulation of glucose and lipid metabolism. *Nature* 2001; **414**: 799–806.
- [84] Kumar PJ, Clark M. Textbook of clinical medicine. In: *Diabetes mellitus and other disorders of metabolism*. London: Saunders; 2005, p. 1069–1121.
- [85] Shetty AK, Kumar SG, Sambaiah K, Salimath PV. Effect of bitter gourd (*Momordica charantia*) on glycaemic status in streptozotocin induced diabetic rats. *Plant Foods Hum Nutr* 2005; **60**: 109–112.
- [86] Hanhineva K, Torronen R, Bondia-Pons I, Pekkinen J, Kolehmainen M, Mykkanen H, et al. Impact of dietary polyphenols on carbohydrate metabolism. *Int J Mol Sci* 2010; **11**: 1365–1402.
- [87] Ismail WFE, Abo-Ghanema II, Saleh RM. Some physiological effects of *Momordica charantia* and *Trigonella foenum-graecum* extracts in diabetic rats as compared with cidofovir®. *World Academy of Science, Engineering and Technology* 2012; **64**: 1206–1214.
- [88] Mohammady I, Elattar S, Mohammed S, Ewais M. An evaluation of anti-diabetic and anti-lipidemic properties of *Momordica charantia* (Bitter Melon) fruit extract in experimentally induced diabetes. *Life Sci J* 2012; **9**(2): 363–374.
- [89] Chen Q, Chan LL, Li ET. Bitter melon (*Momordica charantia*) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. *J Nutr* 2003; **133**: 1088–1093.
- [90] Chen Q, Li ET. Reduced adiposity in bitter melon (*Momordica charantia*) fed rats is associated with lower tissue triglyceride and higher plasma catecholamines. *Br J Nutr* 2005; **93**: 747–754.
- [91] Jayasooriya AP, Sakono M, Yukizaki C, Kawano M, Yamamoto K, Fukuda N. Effects of *Momordica charantia* powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets. *J Ethnopharmacol* 2000; **172**: 331–336.
- [92] Ojewole JA, Adewole SO, Olayiwola G. Hypoglycaemic and hypotensive effects of *Momordica charantia* Linn. (Cucurbitaceae) whole-plant aqueous extract in rats. *Cardiovasc J Afr* 2006; **17**: 227–232.
- [93] Virdi J, Sivakami S, Shahani S, Suthar AC, Banavalikar MM, Biyani MK. Antihyperglycemic effects of three extracts from *Momordica charantia*. *J Ethnopharmacol* 2003; **88**: 107–111.
- [94] Miura T, Itoh C, Iwamoto N, Kato M, Kawai M, Park SR, et al. Hypoglycemic activity of the fruit of the *Momordica charantia* in type 2 diabetic mice. *J Nutr Sci Vitaminol* 2001; **47**: 340–344.
- [95] Zheng D, MacLean PS, Pohnert SC, Knight JB, Olson AL, Winder WW, et al. Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. *J Appl Physiol* 2001; **91**: 1073–1083.
- [96] McCarty MF. Does bitter melon contain an activator of AMP-activated kinase? *Medical Hypotheses* 2004; **63**: 340–343.
- [97] Cheng HL, Huang HK, Chang CI, Tsai CP, Chou CH. A cell-based screening identifies compounds from the stem of *Momordica charantia* that overcome insulin resistance and activate AMP-activated protein kinase. *J Agric Food Chem* 2008; **27**: 6835–6843.
- [98] Huang HL, Hong YW, Wong YH, Chen YN, Chyuan JH, Huang CJ, et al. Bitter melon (*Momordica charantia* L.) inhibits adipocyte hypertrophy and down regulates lipogenic gene expression in adipose tissue of diet-induced obese rats. *Br J Nutr* 2008; **99**: 230–239.
- [99] Shih CC, Lin CH, Lin WL. Effects of *Momordica charantia* on insulin resistance and visceral obesity in mice on high-fat diet. *Diabetes Res Clin Pract* 2008; **81**: 134–143.
- [100] Singh N, Gupta M. Regeneration of β cells in islets of langerhans of pancreas of alloxan diabetic rats by acetone extract of *Momordica charantia* (Linn.) (bitter gourd) fruits. *Indian J Exp Biol* 2007; **45**: 1055–1062.
- [101] Rahman IU, Basir M, Salman M, Idrees M, Khan MI. Bitter melon (*Momordica charantia*) reduces serum sialic acid in type 2 diabetics: Evidence to delay the process of atherosclerosis. *Chin Med* 2011; **2**: 125–129.
- [102] Michael B, Krawinkel MD, Keding GB. Bitter gourd (*Momordica charantia*): A dietary approach to hyperglycemia. *Nutr Rev* 2006; **64**(7): 331–337.
- [103] Diabetes UK. Statement on Karela Capsules. London: Diabetes UK. [Online] Available from: <http://www.diabetes.org.uk/infocentre/inform/karela.htm> [Accessed on 13th June 2006].
- [104] Lakholia AN. The use of bitter gourd in diabetes mellitus. *Antiseptic* 1956; **53**: 608–610.
- [105] Tsi C, Chen EC, Tsay H, Huang C. Wild bitter gourd improves metabolic syndrome: A preliminary dietary supplementation trial. *Nutr J* 2012; **11**: 4.
- [106] Dans AM, Villarruz MV, Jimeno CA, Anthony M, Javelosab U, Chuaa J, et al. The effect of *Momordica charantia* capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. *J Clin Epidemiol* 2007; **60**: 554–559.
- [107] Tongia A, Tongia SK, Dave M. Phytochemical determination and extraction of *Momordica charantia* fruit and its hypoglycemic potentiation of oral hypoglycemic drugs in diabetes mellitus (NIDDM). *Indian J Physiol Pharmacol* 2004; **48**: 241–244.
- [108] John AJ, Cherian R, Subhash HS, Cherian AM. Evaluation of the efficacy of bitter gourd (*Momordica charantia*) as an oral hypoglycemic agent – a randomized controlled clinical trial. *Indian J Physiol Pharm* 2003; **47**: 363–365.
- [109] Ahmad N, Hassan MR, Halder H, Bennoor KS. Effect of *Momordica charantia* (Karolla) extracts on fasting and postprandial serum glucose in NIDDM patients. *Bangladesh Med Res Council Bull* 1999; **25**: 11–13.
- [110] Rivastava Y, Venkatakrishna-Bhatt H, Verma Y. Antidiabetic and adaptogenic properties of *Momordica charantia* extract: an experimental and clinical evaluation. *Phytother Res* 1993; **7**: 285–289.
- [111] Grover JK, Gupta SR. Hypoglycemic activity of seeds of *Momordica charantia*. *Eur J Pharmacol* 1990; **183**: 1026–1027.
- [112] Welihinda J, Arvidson G, Gyfle E, Hellman B, Karlsson E. The insulin-releasing activity of the tropical plant *Momordica charantia*. *Acta Biol Med Germ* 1982; **41**: 1229–1240.
- [113] Akhtar MS. Trial of *Momordica charantia* Linn (Karela) powder in patients with maturity-onset diabetes. *J Pakistan Med Assoc* 1982; **32**: 106–107.
- [114] Leatherdale BA, Panesar RK, Singh G, Atkins TW, Bailey CJ, Bignell AH. Improvement in glucose tolerance due to *Momordica charantia* (karela). *Br Med J* 1981; **282**: 1823–1824.
- [115] Khanna P, Jain SC, Panagariya A, Dixt VP. Hypoglycaemic activity of polypeptide-p from a plant source. *J Nat Prod* 1981; **44**: 648–655.
- [116] Baldwa VS, Bhandari CM, Pangaria A, Goyal RK. Clinical trials in patients with diabetes mellitus of an insulin-like compound obtained from plant source. *Ups J Med Sci* 1977; **82**: 39–41.
- [117] Patel JC, Dhirawani MK, Doshi JC. 'Karella' in the treatment of diabetes mellitus. *Indian J Med Sci* 1968; **22**: 30–32.